Display options
Cite
Golenkina EA, Galkina SI, Dolinnaya NG, et al. Synthetic Hexanucleotides as a Tool to Overcome Excessive Neutrophil Activation Caused by CpG-Containing Oligonucleotides. Pathogens. 2021;10(5)doi: 10.3390/pathogens10050530.
Golenkina, E. A., Galkina, S. I., Dolinnaya, N. G., Arifulin, E. A., Romanova, Y. M., & Sud'ina, G. F. (2021). Synthetic Hexanucleotides as a Tool to Overcome Excessive Neutrophil Activation Caused by CpG-Containing Oligonucleotides. Pathogens (Basel, Switzerland), 10(5), . https://doi.org/10.3390/pathogens10050530
Golenkina, Ekaterina A, et al. "Synthetic Hexanucleotides as a Tool to Overcome Excessive Neutrophil Activation Caused by CpG-Containing Oligonucleotides." Pathogens (Basel, Switzerland) vol. 10,5 (2021). doi: https://doi.org/10.3390/pathogens10050530
Golenkina EA, Galkina SI, Dolinnaya NG, Arifulin EA, Romanova YM, Sud'ina GF. Synthetic Hexanucleotides as a Tool to Overcome Excessive Neutrophil Activation Caused by CpG-Containing Oligonucleotides. Pathogens. 2021 Apr 28;10(5). doi: 10.3390/pathogens10050530. PMID: 33924760; PMCID: PMC8146577.
Copy Download .nbib Format: NLM
Share it on

Pathogens. 2021 Apr 28;10(5). doi: 10.3390/pathogens10050530.

Synthetic Hexanucleotides as a Tool to Overcome Excessive Neutrophil Activation Caused by CpG-Containing Oligonucleotides.

Pathogens (Basel, Switzerland)

Ekaterina A Golenkina, Svetlana I Galkina, Nina G Dolinnaya, Evgenii A Arifulin, Yulia M Romanova, Galina F Sud'ina

Affiliations

  1. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, 119991 Moscow, Russia.
  2. Department of Chemistry, Lomonosov Moscow State University, 119991 Moscow, Russia.
  3. Gamaleya National Research Centre of Epidemiology and Microbiology, 123098 Moscow, Russia.

PMID: 33924760 PMCID: PMC8146577 DOI: 10.3390/pathogens10050530

Abstract

Mimicking bacterial DNA, synthetic CpG-containing oligodeoxyribonucleotides (CpG-ODNs) have a powerful immunomodulatory potential. Their practical application is mainly associated with the production of vaccines, where they are used as adjuvants, as well as in local antimicrobial therapy. CpG-ODNs act on a wide variety of immune cells, including neutrophilic granulocytes. On the one hand, the stimulatory effect provides both the direct implementation of their antimicrobial and fungicidal mechanisms, and an avalanche-like strengthening of the immune signal due to interaction with other participants in the immune process. On the other hand, hyperactivation of neutrophilic granulocytes can have negative consequences. In particular, the formation of unreasonably high amounts of reactive oxygen species leads to tissue damages and, as a consequence, a spontaneous aggravation and prolongation of the inflammatory process. Under physiological conditions, a large number of DNA fragments are present in inflammation foci: both of microbial and self-tissue origin. We investigated effects of several short modified hexanucleotides on the main indicators of neutrophil activation, as well as their influence on the immunomodulatory activity of known synthetic CpG-ODNs. The results obtained show that short oligonucleotides partially inhibit the prooxidant effect of synthetic CpG-ODNs without significantly affecting the ability of the latter to overcome bacteria-induced pro-survival effects on neutrophilic granulocytes.

Keywords: CpG oligonucleotides; apoptosis; modified oligonucleotides; neutrophil; reactive oxygen species

References

  1. Free Radic Res. 2007 Jun;41(6):699-712 - PubMed
  2. J Histochem Cytochem. 1986 Sep;34(9):1109-15 - PubMed
  3. Nature. 2015 Apr 30;520(7549):702-5 - PubMed
  4. Cell Death Differ. 2011 Sep;18(9):1457-69 - PubMed
  5. Immunity. 2018 Apr 17;48(4):649-658.e4 - PubMed
  6. Antioxid Redox Signal. 2014 Mar 1;20(7):1126-67 - PubMed
  7. J Exp Med. 2006 Aug 7;203(8):1999-2008 - PubMed
  8. Eur J Immunol. 2013 Aug;43(8):2101-13 - PubMed
  9. J Leukoc Biol. 2019 Jul;106(1):45-55 - PubMed
  10. Anal Biochem. 1980 Jul 1;105(2):389-97 - PubMed
  11. Front Physiol. 2017 May 30;8:351 - PubMed
  12. Vet Res. 2005 Jul-Aug;36(4):629-43 - PubMed
  13. Nat Protoc. 2006;1(3):1458-61 - PubMed
  14. Expert Opin Biol Ther. 2004 Jun;4(6):937-46 - PubMed
  15. Eur J Immunol. 2004 Jan;34(1):251-62 - PubMed
  16. FEBS J. 2006 Feb;273(3):548-57 - PubMed
  17. Trends Immunol. 2009 Nov;30(11):531-7 - PubMed
  18. Update Cancer Ther. 2008 Mar;3(1):27-32 - PubMed
  19. Free Radic Biol Med. 2007 Oct 1;43(7):995-1022 - PubMed
  20. Microbiol Immunol. 1992;36(9):983-97 - PubMed
  21. Nature. 1995 Apr 6;374(6522):546-9 - PubMed
  22. Nat Commun. 2017 May 22;8:15363 - PubMed

Publication Types

Grant support